Related Experiment Video
Updated: May 16, 2026
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Targeting histone deacetylase in thyroid cancer
Diego Russo1, Cosimo Durante, Stefania Bulotta
1University Magna Graecia of Catanzaro, Department of Health Sciences, Campus S. Venuta, 88100 Catanzaro, Italy. d.russo@unicz.it
Expert Opinion on Therapeutic Targets
|December 14, 2012
Summary
Histone deacetylase (HDAC) inhibitors show promise in treating thyroid cancer by reducing cell proliferation and restoring iodine uptake. These drugs may offer new options for difficult-to-treat thyroid tumors.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Epigenetic alterations, including histone acetylation/deacetylation, are observed in thyroid cancer cells.
- These changes influence cell differentiation and proliferation, potentially driving neoplastic transformation.
- Histone deacetylase (HDAC) inhibitors are emerging as a therapeutic strategy with demonstrated anti-tumor effects.
Purpose of the Study:
- To review the role of histone acetylation in gene expression regulation.
- To summarize epigenetic alterations in thyroid cancer.
- To analyze pre-clinical and clinical data on HDAC inhibitors for thyroid cancer treatment.
Main Methods:
- Overview of histone acetylation-mediated gene expression.
- Identification of epigenetic alterations in thyroid cancer.
- Review of pre-clinical and clinical studies involving HDAC inhibitors.
Main Results:
- HDAC inhibition shows potential for thyroid cancer treatment.
- Reduced proliferation rates and restored iodine-uptake capacity observed in transformed thyrocytes.
- Encouraging results from ongoing pre-clinical and clinical studies.
Conclusions:
- HDACs represent a significant therapeutic target in thyroid cancer.
- HDAC inhibitors demonstrate efficacy in preclinical models and early clinical trials.
- Combination therapy with HDAC inhibitors may benefit treatment-resistant thyroid cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...